Kewalramani Reshma

Kewalramani Reshma, CEO and President of Vertex Pharmaceuticals (VRTX), has filed 39 Form 4 transactions across the single company, with a pronounced sell-side bias in recent activity. The most striking cluster occurred on February 27, 2026, when she executed 13 open-market sales totaling approximately $18.2 million, with individual transactions ranging from $57,780 to $7.72 million. That single-day selling spree dwarfs her only two open-market purchases, which took place on August 6, 2025, and totaled roughly $3.9 million—a buy-to-sell ratio of about 1:7 by dollar value. Over the full filing history, her cumulative sales reach $27.2 million against $3.9 million in purchases, underscoring a consistent monetization pattern. The February 2026 sales were preceded by a series of automatic "F" transactions—shares withheld to cover tax obligations on equity compensation—including a $6.36 million withholding on February 13, 2026, and a $3.17 million event on February 17, 2026. These are mechanical, not discretionary, but they coincide with "A" grants on January 22 and February 17, 2026, valued at zero, indicating new equity awards that triggered the subsequent tax-related sales. The recent data shows 13 sell transactions against just 2 buys, with no acquisitions in the pipeline, reinforcing that the selling is driven by compensation vesting and open-market liquidation rather than fresh accumulation. Notably, the August 2025 purchases—$2.23 million and $1.67 million—represent the only "P" codes in the record, which are typically viewed as the strongest signal of insider conviction. However, those buys have not been repeated in the six months since, and the February 2026 sales suggest a shift toward realizing gains. The pattern is consistent with a CEO managing a large equity position: periodic grants, automatic tax withholdings, and occasional open-market sales, with the recent volume concentrated in a single day. Whether this reflects portfolio diversification or a bearish view is unknowable from the filings alone, but the data clearly shows a net seller over the trailing year.